| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02182401 Details | 2014-07-18 Interventional | 1 | 37 | Midazolam Tolbutamide Healthy | - - | |||
| NCT02181920 Details | 2014-07-18 Interventional | 4 | 6 | Diclofenac Dipyrone Chronic Pain Pain | - - | |||
| NCT02177370 Details | 2014-07-18 Interventional | 3 | 19 | Fenoterol Asthma | - - | |||
| NCT01129960 2010-019100-23 Details | 2014-07-18 Interventional | 3 | 332 | Eslicarbazepine… Diabetic Neurop… Neuralgia Painful Diabeti… | - - | |||
| NCT00744653 Details | 2014-07-18 Interventional | 2 | [1 Refs] | 17 | Bleomycin Breast Neoplasm… Recurrence Breast Cancer | Primary endpoint measure not suitable for evaluation Early termination due to too few objective respondes using the primary endpoint. | ||
| NCT00720629 Details | 2014-07-18 Interventional | 2 | 8 | Antilymphocyte … Methotrexate Tacrolimus Thymoglobulin Visilizumab Graft vs Host D… Graft Versus Ho… | - Study closed early during the first stage, did not proceed to the second stage comparison as planned. Investigators exercised right to close the study prematurely for lack of efficacy, although no protocol-defined end points had been met. | |||
| NCT02081183 Details | 2014-07-17 Interventional | 3 | 16 | Cyclophosphamid… Mycophenolic Ac… Prednisone Lupus Nephritis Nephritis | - Data were not analyzed because the study was terminated early. | |||
| NCT00927212 Details | 2014-07-17 Interventional | 2 | 5 | Ammonium trichl… Dermatitis Dermatitis, Ato… Eczema Atopic Dermatit… | The trial started and halted due sponsor's considerations. - | |||
| NCT00547911 Details | 2014-07-17 Interventional | 1/2 | 14 | Carbidopa Droxidopa Entacapone Autonomic Nervo… Multiple System… Nervous System … Parkinson Disea… Primary Dysauto… Shy-Drager Synd… | Study terminated due to contamination droxidopa Study was prematurely terminated due to a small amount of DOPAL contamination in the droxidopa. Because of the early termination only a small number of subjects were enrolled in each condition. Recently, the FDA has approved droxidopa. | |||
| NCT01125930 Details | 2014-07-16 Interventional | 3 | 68 | Tretinoin Rosacea | Due to slow recruitment and sponsor request study ended early Early termination of study due to slow recruitment and sponsor request resulted in smaller number of subjects analyzed. | |||
| NCT01491633 Details | 2014-07-15 Interventional | 2 | [1 Refs] | 5 | Dasatinib Lung Neoplasms Squamous Cell L… | Safety issues/concerns per DF/HCC PI Due to the toxicity of the study agent no subjects were evaluable for response | ||
| NCT01200264 Details | 2014-07-15 Interventional | 2 | 0 | Apremilast Psoriasis Chronic Plaque … | Contract never executed; withdrawn by sponsor - | |||
| NCT02184286 Details | 2014-07-14 Interventional | 1 | 5 | Nevirapine Saquinavir HIV Infections | - - | |||
| NCT02182765 Details | 2014-07-14 Interventional | 1 | 8 | Abacavir Amprenavir Nevirapine HIV Infections | - - | |||
| NCT02176200 Details | 2014-07-14 Interventional | 3 | 3 | Fenoterol Fenoterol, ipra… Ipratropium Lung Diseases Lung Diseases, … Pulmonary Disea… | - - | |||
| NCT02176187 Details | 2014-07-14 Interventional | 3 | 3 | Fenoterol Fenoterol, ipra… Ipratropium Lung Diseases Lung Diseases, … Pulmonary Disea… | - - | |||
| NCT01904253 2012-004793-26 Details | 2014-07-14 Interventional | 2 | 18 | Amrubicin Topotecan Lung Neoplasms Small Cell Lung… Small Cell Lung… | The preliminary data does not suggest any safety signal, but an ad hoc interim analysis showed
an imbalance of PFS between the two arms - | |||
| NCT01418742 Details | 2014-07-14 Interventional | 2 | 11 | Doxycycline Panitumumab Carcinoma Colorectal Neop… Colorectal Carc… | Recruitement did not meet expectations. Prev. differentiation of RAS-wild-type and mutated RAS
are not in accordance with the scientific rank anymore. - | |||
| NCT01301612 Details | 2014-07-14 Interventional | 2 | 0 | Cisplatin Nimotuzumab Adenocarcinoma Carcinoma Carcinoma, Aden… Uterine Cervix … | Regulatory requirement. A phase III study is being designed. - | |||
| NCT00709618 Details | 2014-07-14 Interventional | 2 | 44 | Lapatinib Vinorelbine Breast Neoplasm… Neoplasms, Brea… | Evolving standard of care practices in this disease setting was limiting enrolment and leading
to a delay in delivering this study information to the public. The study was terminated due to low screening and a low enrollment rate after 3 years. |